A strategic partnership has been announced to develop Saudi Arabia’s first fully integrated, modular advanced therapy medicinal product (ATMP) manufacturing campus. 17 June 2025
Medicines for Europe, a manufacturers of generic and biosimilar trade group, today presented five trade policy recommendations to strengthen global access to medicines and enhance the competitiveness of the off-patent pharmaceutical sector in a seminar with the European Commission and Member States representatives. 17 June 2025
Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global Phase III VERONA trial. 17 June 2025
Some 55 attorneys general (AGs), representing all eligible states and US territories, have agreed to sign on to a $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family. 17 June 2025
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
Australian biotech CSL has announced that the US Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. 17 June 2025
South Korea’s clinical-stage biotech D&D Pharmatech saw its share leap as much as 30% as it revealed “remarkably positive” results on its metabolic dysfunction-associated steatohepatitis (MASH) candidate. 17 June 2025
US trade association PhRMA (Pharmaceutical Research and Manufacturers of America) has cited a new IQVIA study that found that Medicare Part D plans routinely deny access to prescribed medicines for patients with newly-diagnosed chronic conditions. 17 June 2025
Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025
Israel’s Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. 17 June 2025
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Scientists at The Institute of Cancer Research, London, claim to have discovered what may cause some treatments to stop working in people living with bowel cancer. 16 June 2025
French drug developer Averoa today announced that the European Commission (EC) has granted marketing authorization for Xoanacyl (ferric citrate coordination complex). 16 June 2025
A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy. 16 June 2025
Swiss pharma giant Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease (PD). 16 June 2025
TTAM Research Institute, a nonprofit public benefit corporation based in California and led by 23andMe co-founder and former chief executive Anne Wojcicki, is to buy the latter company’s assets. 16 June 2025
French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST Phase IV study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. 16 June 2025
China’s National Medical Products Administration (NMPA) held a meeting last week to conduct the 2024 annual review of the quality management system (QMS) in vaccine regulation and pharmaceutical manufacturing inspection. 16 June 2025
A strategic partnership has been announced to develop Saudi Arabia’s first fully integrated, modular advanced therapy medicinal product (ATMP) manufacturing campus. 17 June 2025
Medicines for Europe, a manufacturers of generic and biosimilar trade group, today presented five trade policy recommendations to strengthen global access to medicines and enhance the competitiveness of the off-patent pharmaceutical sector in a seminar with the European Commission and Member States representatives. 17 June 2025
Pharma majors AbbVie and Roche were both trading lower early Tuesday after top-line results were announced from the global Phase III VERONA trial. 17 June 2025
Some 55 attorneys general (AGs), representing all eligible states and US territories, have agreed to sign on to a $7.4 billion settlement with Purdue Pharma and its owners, the Sackler family. 17 June 2025
US pharma major Eli Lilly (today announced a definitive agreement to acquire Verve Therapeutics, a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, sending Verve’s shares up 77.7% to $11.15 in premarket trading. 17 June 2025
Australian biotech CSL has announced that the US Food and Drug Administration (FDA) has approved Andembry (garadacimab-gxii), the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. 17 June 2025
South Korea’s clinical-stage biotech D&D Pharmatech saw its share leap as much as 30% as it revealed “remarkably positive” results on its metabolic dysfunction-associated steatohepatitis (MASH) candidate. 17 June 2025
US trade association PhRMA (Pharmaceutical Research and Manufacturers of America) has cited a new IQVIA study that found that Medicare Part D plans routinely deny access to prescribed medicines for patients with newly-diagnosed chronic conditions. 17 June 2025
Shares of USA-based NextCure slumped 26% to $0.50 on Monday, after the company announced a strategic partnership with China-based Simcere Zaiming, subsidiary of Simcere Pharmaceutical Group Ltd to develop a therapy for the treatment of solid tumors. 17 June 2025
Israel’s Teva Pharmaceutical Industries and Shanghai Fosun Pharmaceutical have entered a strategic partnership for the development of investigational TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy. 17 June 2025
Cambridge, UK-based Maxion Therapeutics today announced the appointment of Dr Stefan Härtle as chief development officer, effective immediately. 17 June 2025
Scientists at The Institute of Cancer Research, London, claim to have discovered what may cause some treatments to stop working in people living with bowel cancer. 16 June 2025
French drug developer Averoa today announced that the European Commission (EC) has granted marketing authorization for Xoanacyl (ferric citrate coordination complex). 16 June 2025
A second case of acute liver failure (ALF) resulting in the death has been reported in a young recipient of Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for Duchenne muscular dystrophy. 16 June 2025
Swiss pharma giant Roche announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-stage Parkinson’s disease (PD). 16 June 2025
TTAM Research Institute, a nonprofit public benefit corporation based in California and led by 23andMe co-founder and former chief executive Anne Wojcicki, is to buy the latter company’s assets. 16 June 2025
French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST Phase IV study of adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting asthma. 16 June 2025
China’s National Medical Products Administration (NMPA) held a meeting last week to conduct the 2024 annual review of the quality management system (QMS) in vaccine regulation and pharmaceutical manufacturing inspection. 16 June 2025
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A biotechnology company focused on developing novel antibody therapies targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes.